Evaluation of response rate to hydroxycobalamin treatment in patients with methylmalonic acidemia

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211207053311N1

Enrollment

Registered

2022-03-07

Start date

2022-02-04

Completion date

Unknown

Last updated

2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

methylmalonic acidemia. E71.120

Interventions

Intervention group:.

Eligibility

Sex/Gender

All

Age

No minimum to 18 Years

Inclusion criteria

Inclusion criteria: patients with isolated methylmalonic acidemia or methylmalonic acidemia with hemocyctinuria confirmed in MS/MS and urine organic acid or genetic

Exclusion criteria

Exclusion criteria: suspicious patients that have not certain diagnosis and poor control patients that have not cooperation

Design outcomes

Primary

Measure	Time frame
Decrease more than 50 percent in urine methylmalonic acid considered positive and the patient is responsible to hydroxycobalamine. Timepoint: urine methylmalonic acid before starting the intervention and then 3 days after received hydroxycobalamine in stable patients and after 7 days in unstable patients. Method of measurement: evaluation of urine methylmalonic acid.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactafsane nazari

Mashhad University of Medical Sciences

nazari.afsane@gmail.com+98 51 3501 2620

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026